The creation of retatrutide, a novel dual agonist targeting both GLP-1 and GIP receptors, involves a complex multi-step chemical process. Early routes focused on amino acid chain section coupling, utilizing solid-phase synthesis methodologies to build the long protein sequence. Subsequent research has explored different approaches, including enzyma